Evicenter
Zepbound (tirzepatide) in Chronic weight management
Manufacturer
Lilly USA, LLC
Prescribing information
Zepbound (opens in a new tab)
Questions
33
Last updated

All questions

Clinical trials: Zepbound (tirzepatide) in chronic weight management

11 questions · 2 sources

Study results

How much weight do people lose on Zepbound (SURMOUNT-1)?

“Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intention-to-treat population includes all randomly assigned patients. For Study 1 at Week 72, body weight was missing for 21.6%, 10.2%, 10.5%, and 9.4% of patients randomly assigned to placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, respectively. For Study 2 at Week 72, body weight was missing for 11.1%, 4.8%, and 8.4% of patients randomly assigned to placebo, ZEPBOUND 10 mg, and 15 mg, respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using logistic regression adjusted for baseline value. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. Study 1 Study 2 Intention-to-Treat (ITT) Populationa Placebo N = 643 ZEPBOUND 5 mg N = 630 ZEPBOUND 10 mg N = 636 ZEPBOUND 15 mg N = 630 Placebo N = 315 ZEPBOUND 10 mg N = 312 ZEPBOUND 15 mg N = 311 Body Weight Baseline mean (kg) 104.8 102.9 105.8 105.6 101.7 100.9 99.6 % Change from baselineb -3.1 -15.0 -19.5 -20.9 -3.2 -12.8 -14.7 % Difference from placebob (95% CI) -11.9 (-13.4, -10.4)d -16.4 (-17.9, -14.8)d -17.8 (-19.3, -16.3)d -9.6 (-11.1, -8.1)d -11.6 (-13.0, -10.1)d” (opens the source at this quote in a new tab)

Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Study 1 of the Prescribing Information has the same duration and enrollment (72 weeks, 2,539 patients) as SURMOUNT-1 on the Zepbound HCP site.

Zepbound: how many people lose 5%, 10%, 15%, or 20% of their weight?

Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Studies 1 and 2 have the same duration and enrollment as SURMOUNT-1 (2,539 patients) and SURMOUNT-2 (938 patients) on the Zepbound HCP site.

How many people on Zepbound lose 25% or more of their body weight?

Zepbound in type 2 diabetes: how much weight do people lose (SURMOUNT-2)?

Applies to Weight reduction in adults with overweight or obesity and type 2 diabetes (SURMOUNT-2)

Note: In the Table 2 rows, the last three columns are Study 2: placebo, ZEPBOUND 10 mg, and 15 mg. Study 2 of the Prescribing Information has the same duration and enrollment (72 weeks, 938 patients) as SURMOUNT-2 on the Zepbound HCP site.

Does Zepbound add weight loss after an intensive lifestyle program (SURMOUNT-3)?

“Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug. a The intent-to-treat population included only randomized patients with ≥5% weight loss at Week 0 after 12 weeks of intensive lifestyle intervention. During the 12-week lead-in period, 227 of 806 patients (28.2%) discontinued from the study. Of these 141 (17.5%) discontinued due to not achieving the randomization criteria of ≥5% weight reduction. b The intent-to-treat population includes all randomly assigned patients. For Study 3 at Week 72, body weight was missing for 23.6% and 8.7% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg). The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). c Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. d Analyzed using logistic regression adjusted for baseline value. e p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. Study 3 N = 579a Body Weight Mean (kg) at Week -12 109.5 Intention-to-Treat (ITT) Populationa,b Placebo N = 292 ZEPBOUND MTD (10 mg or 15 mg) N = 287 Body Weight Mean (kg) at Week 0 101.3 102.5 % Change from randomization at Week 72c 2.5 -18.4 % Difference from placebo, at Week 72c (95% CI) -20.8 (-23.2, -18.5)e % of Patients losing ≥5% body weight 16.5 87.5 % Difference from placebo (95% CI) 71.1 (63.6, 78.5)d,e % of Patients losing ≥10% body weight 8.9 76.7 % Difference from placebo (95% CI) 67.9 (60.7, 75.1)d,e % of Patients losing ≥15% body weight 4.2 65.4 % Difference from placebo (95% CI) 61.3 (54.5, 68.1)d,e % of Patients losing ≥20% body weight 2.2 44.7 % Difference from placebo (95% CI) 42.6 (36.0, 49.1)d,e” (opens the source at this quote in a new tab)

Note: Table 4 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. Study 3 of the Prescribing Information has the same design and enrollment (806 enrolled, 579 randomized) as SURMOUNT-3 on the Zepbound HCP site.

Do people regain weight after stopping Zepbound (SURMOUNT-4)?

Note: Table 6 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. The week 88 values from week 0 are from the clinical data page of the Zepbound HCP site. Study 4 of the Prescribing Information has the same design and enrollment (783 enrolled, 670 randomized) as SURMOUNT-4.

Zepbound vs Wegovy: which causes more weight loss (SURMOUNT-5)?

Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site, which cites Aronne et al., N Engl J Med 2025; the Zepbound Prescribing Information does not describe this trial.

Is Zepbound weight loss maintained at 5 mg or after stopping (SURMOUNT-MAINTAIN)?

Note: SURMOUNT-MAINTAIN results are from the clinical data page of the Zepbound HCP site, which cites Horn et al., Lancet 2026; the Zepbound Prescribing Information does not describe this trial.

How much weight loss do people keep off on Zepbound (SURMOUNT-MAINTAIN)?

Note: The maintenance percentages are among participants who reached a body weight plateau during the 60-week open-label weight-loss period. SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.

How much weight do adults 65 and older lose on Zepbound?

Applies to Adults aged 65 and older with obesity, or with overweight and at least one weight-related comorbid condition

Does Zepbound lower blood pressure, cholesterol, and triglycerides?

“Table 3: Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intention-to-treat population includes all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using log-transformed data. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors. g Baseline value is the geometric mean. Study 1 Study 2 Intention-to-Treat (ITT) Populationa Placebo N = 643 ZEPBOUND 5 mg N = 630 ZEPBOUND 10 mg N = 636 ZEPBOUND 15 mg N = 630 Placebo N = 315 ZEPBOUND 10 mg N = 312 ZEPBOUND 15 mg N = 311 Waist Circumference (cm) Baseline mean 114.0 113.2 114.8 114.4 116.0 114.2 114.6 Change from baselineb -4.0 -14.0 -17.7 -18.5 -3.3 -10.8 -13.1 Difference from placebob (95% CI) -10.1 (-11.6, -8.6)e -13.8 (-15.2, -12.3)d -14.5 (-15.9, -13.0)d -7.4 (-9.0, -5.9)d -9.8 (-11.2, -8.3)d Systolic Blood Pressure (mmHg) Baseline mean 122.9 123.6 123.8 123.0 131.0 130.6 130.0 Change from baselineb -1.0 -6.6 -7.7 -7.4 -1.2 -5.6 -7.1 Difference from placebob (95% CI) -5.6 (-7.2, -3.9)e -6.7 (-8.4, -5.0)e -6.4 (-8.0, -4.8)e -4.4 (-6.7, -2.1)e -5.9 (-8.3, -3.6)e Diastolic Blood Pressure (mmHg) Baseline mean 79.6 79.3 79.9 79.3 79.4 80.2 79.7 Change from baselineb -0.8 -4.9 -5.0 -4.5 -0.3 -2.1 -2.9 Difference from placebob (95% CI) -4.1 (-5.2, -3.0)e -4.2 (-5.3, -3.0)e -3.7 (-4.8, -2.7)e -1.8 (-3.3, -0.4)e -2.7 (-4.2, -1.2)e Pulse Rate (beats per minute) Baseline mean 72.9 72.4 71.8 72.4 74.8 75.9 75.6 Change from baselinef 0.1 0.6 2.3 2.6 -0.5 0.6 1.0 Difference from placebof (95% CI) 0.5 (-0.5, 1.5)e 2.2 (1.2, 3.2)e 2.5 (1.5, 3.4)e 1.2 (-0.1, 2.5)e 1.5 (0.2, 2.8)e Total Cholesterol (mg/dL) Baseline meang 187.5 187.1 190.6 187.5 174.9 173.9 167.0 % change from baselineb -1.8 -3.8 -4.4 -6.3 2.8 -2.8 -1.0 Relative difference from placebob (95% CI) -2.1 (-4.5, 0.4)c,e -2.7 (-5.1, -0.2)c,e -4.6 (-6.8, -2.2)c,e -5.5 (-8.7, -2.2)c,e -3.8 (-7.1, -0.3)c,e LDL Cholesterol (mg/dL) Baseline meang 109.4 108.7 112.3 109.3 92.4 90.5 85.7 % change from baselineb -1.7 -4.6 -5.6 -7.1 7.4 1.8 4.1 Relative difference from placebob (95% CI) -2.9 (-6.6, 0.9)c,e -4.0 (-7.5, -0.5)c,e -5.5 (-8.9, -2.0)c,e -5.2 (-10.1, 0.1)c,e -3.0 (-8.4, 2.6)c,e HDL Cholesterol (mg/dL) Baseline meang 46.6 47.6 47.6 47.6 42.7 43.8 42.2 % change from baselineb -0.7 6.9 9.2 8.0 0.2 8.2 9.7 Relative difference from placebob (95% CI) 7.7 (4.6, 10.8)c,e 9.9 (6.7, 13.2)c,e 8.7 (5.7, 11.8)c,e 8.0 (4.2, 11.8)c,e 9.5 (5.6, 13.5)c,e Non-HDL Cholesterol (mg/dL) Baseline meang 138.3 137.0 140.4 137.5 129.6 127.2 121.9 % change from baselineb -2.3 -8.0 -9.4 -11.7 3.7 -6.6 -5.2 Relative difference from placebob (95% CI) -5.8 (-8.9, -2.6)c,e -7.2 (-10.3, -4.1)c,e -9.6 (-12.4, -6.6)c,e -9.9 (-14.1, -5.6)c,e -8.5 (-12.9, -4.0)c,e Triglycerides (mg/dL) Baseline meang 130.8 128.7 125.7 128.1 165.0 158.8 158.5 % change from baselineb -5.6 -21.2 -23.8 -29.1 -3.3 -27.1 -27.3 Relative difference from placebob (95% CI) -16.5 (-21.2, -11.4)c,e -19.3 (-23.9, -14.4)c,e -24.9 (-29.1, -20.4)c,e -24.6 (-30.0, -18.7)c,e -24.8 (-30.3, -18.9)c,e” (opens the source at this quote in a new tab)

Note: Table 3 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg; footnote e marks results not controlled for type I error. The clinical data page of the Zepbound HCP site reports HDL cholesterol, systolic blood pressure, and triglycerides for pooled Zepbound doses in SURMOUNT-1 as controlled for type I error.